论文部分内容阅读
MTX为中低危妊娠滋养细胞肿瘤(GTN)最常用的化疗药物,但有10％～25％病人最终对MTX耐药。何为最理想的MTX剂量及投药方式,现尚未定论。为达到提高化疗药物剂量及缩短疗程问隔可能增加癌细胞杀伤比率,提高疗效及减少耐药的日的,多伦多大学医院自1970年开始采用高剂量MTX辅加叶酸解救方案治疗GTN病人。本组包括85例中低危GTN病人。诊断标准为葡萄胎排空后有连续两周内三次血清β-hCG检测无下降或曾有回升。
MTX is the most commonly used chemotherapy drug for low-to-medium risk gestational trophoblastic tumors (GTN), but 10% to 25% of patients eventually become resistant to MTX. What is the ideal MTX dosage and method of administration has not yet been finalized. In order to increase the dose of chemotherapeutic drugs and shorten the treatment interval, it may increase the killing rate of cancer cells, increase the curative effect, and reduce the day of drug resistance. Since the year 1970, the University of Toronto Hospital has used high-dose MTX supplemental folic acid rescue programs to treat patients with GTN. This group included 85 patients with low-risk GTN. The diagnostic criteria were that there were no declines in serum β-hCG levels in the three consecutive weeks after hydatidiform mole evacuation or there was a rebound.